Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | July 28, 2020 | July 29, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date July 28, 2020 · Filed July 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 124,999 |
Last balance in matching sequence
After 2020-07-28 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-07-28 · Conversion · Acquired 41,666 · Balance 74,999 F1: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F2: The Reporting Person is a trustee of the Tjian Belcher Revocable Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Row 2 · 2020-07-28 · Conversion · Acquired 50,000 · Balance 124,999 F1: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F2: The Reporting Person is a trustee of the Tjian Belcher Revocable Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Trust | 0 |
Reported balance
After 2020-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-28 · Conversion · Disposed 41,666 · Balance 0 F1: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F2: The Reporting Person is a trustee of the Tjian Belcher Revocable Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Trust | 0 |
Reported balance
After 2020-07-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-07-28 · Conversion · Disposed 50,000 · Balance 0 F1: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F2: The Reporting Person is a trustee of the Tjian Belcher Revocable Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.
F2: The Reporting Person is a trustee of the Tjian Belcher Revocable Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2020 Filed Jul 29, 2020 17:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | ConversionSeries B Preferred Stock · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043956 · doc4.xml · derivative · entry 4 Tjian Robert · CIK 0001817230 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The Reporting Person is a trustee of the Tjian Belcher Revocable Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 17:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | ConversionSeries A-2 Preferred Stock · Derivative | 41,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043956 · doc4.xml · derivative · entry 3 Tjian Robert · CIK 0001817230 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 41,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The Reporting Person is a trustee of the Tjian Belcher Revocable Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 17:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | ConversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-043956 · doc4.xml · nonDerivative · entry 2 Tjian Robert · CIK 0001817230 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 124,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The Reporting Person is a trustee of the Tjian Belcher Revocable Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 17:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | ConversionCommon Stock | 41,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-043956 · doc4.xml · nonDerivative · entry 1 Tjian Robert · CIK 0001817230 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 74,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The Reporting Person is a trustee of the Tjian Belcher Revocable Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.